Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34

Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective

Exelixis (EXEL) announced that its partner Daiichi Sankyo (DSNKY) has reported positive top-line results from a phase 3 pivotal trial of esaxerenone, a product of the companies' prior research collaboration, in patients with essential hypertension in Japan. With the trial achieving its primary endpoint, Daiichi Sankyo has communicated its intention to submit a Japanese regulatory application for esaxerenone for an essential hypertension indication in the first quarter of 2018. In March 2006, Daiichi Sankyo and Exelixis entered into a research collaboration agreement to discover, develop and commercialize novel therapies targeting the mineralocorticoid receptor, or MR. Under the terms of the agreement, Daiichi Sankyo has exclusive global development, manufacturing, and commercialization rights for the compounds. Esaxerenone, a non-steroidal, selective novel MR blocker, is one of the compounds identified during the research collaboration, and has subsequently been developed by Daiichi Sankyo. As esaxerenone advances, Exelixis is eligible for substantial clinical development, regulatory, and commercialization milestones, as well as double-digit royalties on sales. The positive trial, ESAX-HTN, is a randomized, double-blind, three-arm parallel group comparison study evaluating the efficacy and safety of esaxerenone versus eplerenone in patients with essential hypertension in Japan. The primary endpoint is sitting systolic blood pressure, or SBP, / diastolic blood pressure, or DBP, change from baseline after 12 weeks of treatment, and the secondary endpoint is mean 24-hour SBP/DBP change from baseline after 12 weeks of treatment. The trial enrolled 1,001 patients at approximately 40 clinical sites in Japan. Preliminary and ongoing analyses have indicated no significant safety concerns in the ESAX-HTN study. Daiichi Sankyo plans to disclose the detailed study results at future scientific meetings.

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

  • 25

    Sep

  • 25

    Sep

EXEL Exelixis
$24.47

-3.54 (-12.64%)

09/12/17
NEED
09/12/17
NO CHANGE
NEED
Exelixis data positive, says Needham
Needham analyst Chad Messer says that a study on Exelixis' advanced renal cell carcinoma treatment, Cabozantinib, indicated that the drug's positive impact on progression free survival was greater than shown in previous studies. The analyst thinks that all of the data on Cabozantinib has been positive, and Messer continues to believe that checkpoint inhibitors will be used in conjunction with the drug, rather than as a substitute for it. He keeps a $30 price target and a Buy rating on Exelixis.
09/14/17
RBCM
09/14/17
INITIATION
Target $32
RBCM
Outperform
Exelixis initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Exelixis with an Outperform and a $32 price target telling investors cabozantinib is poised to become an oncology blockbuster and sees scarcity value as a standalone company. MaCKay sees expansion into 1L kidney cancer and liver cancer leading to $3B+ in additional peak global sales potential.
09/22/17
LEER
09/22/17
DOWNGRADE
LEER
Market Perform
Exelixis downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Exelixis to Market Perform and lowered its price target to $28 from $34 saying fundamentals are strong but shares are fairly valued. Schmidt remains constructive on the long-term potential of Cabometyx in combination with immune-checkpoint inhibitors, but believes the commercial opportunity in HCC could be smaller than anticipated and lowered his long-term forecast below consensus.
09/22/17
RHCO
09/22/17
NO CHANGE
RHCO
Exelixis trial likely to be continued, says SunTrust
SunTrust analyst Peter Lawson says that the trial of Exelixis' cabozantinib.in liver cancer will most likely be continued through 2018. He views this scenario as "neutral to negative" for the stock. However, he recommends buying the shares on any weakness, citing what he sees as upcoming positive catalysts, including opportunities in bladder, breast and lung, new data, "and potential revenue beats from broadening use and 1H18 label expansion." He keeps a $33 price target and a Buy rating on the shares.
DSNKY Daiichi Sankyo
$23.03

0.17 (0.74%)

TODAY'S FREE FLY STORIES

ERI

Eldorado Resorts

$33.55

1.1 (3.39%)

08:16
02/20/18
02/20
08:16
02/20/18
08:16
Initiation
Eldorado Resorts initiated  »

Eldorado Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

DIN

DineEquity

$54.67

-0.29 (-0.53%)

08:15
02/20/18
02/20
08:15
02/20/18
08:15
Conference/Events
DineEquity to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 26

    Feb

08:15
02/20/18
02/20
08:15
02/20/18
08:15
General news
Canada wholesale trade preview »

Canada wholesale trade…

HD

Home Depot

$186.97

1.7 (0.92%)

08:15
02/20/18
02/20
08:15
02/20/18
08:15
Recommendations
Home Depot analyst commentary  »

Home Depot weakness would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 30

    May

FOX

21st Century Fox

$37.04

0.39 (1.06%)

, FOXA

21st Century Fox

$37.46

0.5 (1.35%)

08:14
02/20/18
02/20
08:14
02/20/18
08:14
Periodicals
Fox extends Sky News guarantee to secure bid approval, Reuters reports »

Rupert Murdoch's…

FOX

21st Century Fox

$37.04

0.39 (1.06%)

FOXA

21st Century Fox

$37.46

0.5 (1.35%)

SKYAY

Sky

$61.77

0.025 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 01

    Mar

  • 05

    Mar

MDT

Medtronic

$83.31

0.37 (0.45%)

08:14
02/20/18
02/20
08:14
02/20/18
08:14
Hot Stocks
Medtronic says making progress towards surgical robotics platform launch »

Says saw mid-single digit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

TSCO

Tractor Supply

$67.32

-1.82 (-2.63%)

08:13
02/20/18
02/20
08:13
02/20/18
08:13
Conference/Events
Tractor Supply to hold a meeting »

2018 Investment Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

DRIO

DarioHealth

$1.46

-0.03 (-2.01%)

, AMZN

Amazon.com

$1,448.69

-13.07 (-0.89%)

08:12
02/20/18
02/20
08:12
02/20/18
08:12
Hot Stocks
DarioHealth to sell Dario Blood Glucose Monitoring System on Amazon.com »

DarioHealth (DRIO)…

DRIO

DarioHealth

$1.46

-0.03 (-2.01%)

AMZN

Amazon.com

$1,448.69

-13.07 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

08:12
02/20/18
02/20
08:12
02/20/18
08:12
Hot Stocks
Perrigo names Ronald Winowiecki as CFO »

Perrigo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

AXU

Alexco Resource

$1.38

-0.03 (-2.13%)

08:12
02/20/18
02/20
08:12
02/20/18
08:12
Initiation
Alexco Resource initiated  »

Alexco Resource initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$8.76

0.65 (8.01%)

08:11
02/20/18
02/20
08:11
02/20/18
08:11
Hot Stocks
Fate Therapeutics announces first subject treated with FATE-NK100 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

X

U.S. Steel

$44.75

5.76 (14.77%)

, STLD

Steel Dynamics

$49.40

2.26 (4.79%)

08:11
02/20/18
02/20
08:11
02/20/18
08:11
Recommendations
U.S. Steel, Steel Dynamics, Nucor, AK Steel analyst commentary  »

U.S. Steel a key…

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

NUE

Nucor

$68.54

2.96 (4.51%)

AKS

AK Steel

$5.96

0.72 (13.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEC

Vectrus

$28.13

0.26 (0.93%)

08:10
02/20/18
02/20
08:10
02/20/18
08:10
Hot Stocks
Vectrus wins $108M U.S. Army contract »

Vectrus Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 14

    Jun

MNLO

Menlo Therapeutics

$34.88

-0.44 (-1.25%)

08:10
02/20/18
02/20
08:10
02/20/18
08:10
Hot Stocks
Menlo Therapeutics Phase 2 study for chronic pruritus published in JAAD »

Menlo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTES

Gates Industrial

$18.29

-0.09 (-0.49%)

08:10
02/20/18
02/20
08:10
02/20/18
08:10
Initiation
Gates Industrial initiated  »

Gates Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMID

American Midstream Partners

$12.10

-0.25 (-2.02%)

, DKL

Delek Logistics

$31.15

-0.35 (-1.11%)

08:09
02/20/18
02/20
08:09
02/20/18
08:09
Hot Stocks
American Midstream Partners to sell refined products terminalling business »

American Midstream…

AMID

American Midstream Partners

$12.10

-0.25 (-2.02%)

DKL

Delek Logistics

$31.15

-0.35 (-1.11%)

GPP

Green Plains Partners

$18.00

0.2 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

OLED

Universal Display

$154.95

-7.05 (-4.35%)

08:08
02/20/18
02/20
08:08
02/20/18
08:08
Technical Analysis
Technical Take: Universal Display trades lower in pre-market, analyst action »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

CHH

Choice Hotels

$80.50

-0.1 (-0.12%)

08:07
02/20/18
02/20
08:07
02/20/18
08:07
Earnings
Breaking Earnings news story on Choice Hotels »

Choice Hotels sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

NKE

Nike

$68.30

0.01 (0.01%)

, SNAP

Snap

$20.42

0.67 (3.39%)

08:06
02/20/18
02/20
08:06
02/20/18
08:06
Periodicals
Nike unveils latest Air Jordan sneakers on Snapchat app, Recode reports »

Nike (NKE) unveiled its…

NKE

Nike

$68.30

0.01 (0.01%)

SNAP

Snap

$20.42

0.67 (3.39%)

SHOP

Shopify

$137.53

-0.42 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

  • 18

    Mar

EYEN

Eyenovia

$9.00

0.25 (2.86%)

08:06
02/20/18
02/20
08:06
02/20/18
08:06
Initiation
Eyenovia initiated  »

Eyenovia initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

CHH

Choice Hotels

$80.50

-0.1 (-0.12%)

08:06
02/20/18
02/20
08:06
02/20/18
08:06
Earnings
Choice Hotels sees FY18 adjusted EPS $3.54-$3.66, consensus $3.49 »

To facilitate the review…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

CBRL

Cracker Barrel

$173.74

-1.05 (-0.60%)

08:05
02/20/18
02/20
08:05
02/20/18
08:05
Earnings
Breaking Earnings news story on Cracker Barrel »

Cracker Barrel sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 06

    Jun

CBRL

Cracker Barrel

$173.74

-1.05 (-0.60%)

08:05
02/20/18
02/20
08:05
02/20/18
08:05
Earnings
Cracker Barrel raises FY18 EPS view to $9.30-$9.50 from $8.75-$8.90 »

FY18 consensus $9.11.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 06

    Jun

VERI

Veritone

08:04
02/20/18
02/20
08:04
02/20/18
08:04
Recommendations
Veritone analyst commentary  »

Veritone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

FLS

Flowserve

$44.05

1.18 (2.75%)

08:04
02/20/18
02/20
08:04
02/20/18
08:04
Upgrade
Flowserve rating change  »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.